 In Japan there is a controversy for the treatment of S-1 refractory gastric cancer. The controversy is continuing S-1 like FOLFOX to FOLFIRI or not as a second-line. After the successful adjuvant S-1 results ACTS-GC trial, the same problem will occur in the patients who are recurrent from adjuvant S-1. 